Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women

Rossella E Nappi, Ellis Martini, Laura Cucinella, Silvia Martella, Lara Tiranini, Alessandra Inzoli, Emanuela Brambilla, David Bosoni, Chiara Cassani, Barbara Gardella, Rossella E Nappi, Ellis Martini, Laura Cucinella, Silvia Martella, Lara Tiranini, Alessandra Inzoli, Emanuela Brambilla, David Bosoni, Chiara Cassani, Barbara Gardella

Abstract

Vaginal health is an essential component of active and healthy aging in women at midlife and beyond. As a consequence of hormonal deprivation and senescence, the anatomy and function of urogenital tissues are significantly affected and vulvovaginal atrophy (VVA) may occur. In a high proportion of postmenopausal women, progressive and chronic VVA symptoms have a strong impact on sexual function and quality of life. The new definition of genitourinary syndrome of menopause (GSM) comprises genital symptoms (dryness, burning, itching, irritation, bleeding), sexual symptoms (dyspareunia and other sexual dysfunctions) and urinary symptoms (dysuria, frequency, urgency, recurrent urinary infections). Many variables (age, sexual activity and partnership status) influence the clinical impact VVA/GSM symptoms and attitudes of elderly women to consult for receiving effective treatments. Psychosocial factors play a critical role in sexual functioning, but the integrity of the urogenital system is as well important affecting many domains of postmenopausal women's health, including sexual function. Several international surveys have extensively documented the need to improve VVA/GSM management because of the strong impact on women's daily life and on couple's intimacy. Health care providers (HCPs) need to be proactive in the early recognition of VVA/GSM in order to preserve urogenital and sexual longevity, by using hormonal and non-hormonal strategies. The clinical diagnosis is based on genital examination to identify objective signs and on the use of subjective scales to rate most bothersome symptoms (MBS), especially vaginal dryness. Recent studies point to the importance of addressing VVA/GSM as a potential early marker of poor general health in analogy with vasomotor symptoms. Therefore, a standard of VVA/GSM care in elderly women is desirable to enhance physical, emotional and mental well-being.

Keywords: aging; dyspareunia; female sexual dysfunction (FSD); genito-urinary syndrome of menopause (GSM); longevity; quality of life (QoL); vaginal dryness; vulvovaginal atrophy (VVA).

Figures

Figure 1
Figure 1
A very simple check-list to diagnose VVA/GSM in routine clinical practice.

References

    1. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1684–735. 10.1016/S0140-6736(18)31891-9
    1. Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. (2010) 13:419–28. 10.3109/13697137.2010.507886
    1. Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause—global prevalence, physiology and implications. Nat Rev Endocrinol. (2018) 14:199–215. 10.1038/nrendo.2017.180
    1. Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, et al. . Menopause. Nat Rev Dis Primers. (2015) 1:15004. 10.1038/nrdp.2015.54
    1. Davis SR, Wahlin-Jacobsen S. Testosterone in women–the clinical significance. Lancet Diabetes Endocrinol. (2015) 3:980–92. 10.1016/S2213-8587(15)00284-3
    1. Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, et al. . Menopause accelerates biological aging. Proc Natl Acad Sci USA. (2016) 113:9327–32. 10.1073/pnas.1604558113
    1. Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J, et al. . Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas. (2015) 82:308–13. 10.1016/j.maturitas.2015.07.020
    1. Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother. (2015) 16:875–87. 10.1517/14656566.2015.1020791
    1. Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. (2017) 92:1842–9. 10.1016/j.mayocp.2017.08.019
    1. Shifren JL. Genito-urinary syndrome of menopause. Clin Obstet Gynecol. (2018) 61:508–16. 10.1097/GRF.0000000000000380
    1. Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. (2018) 10:387–95. 10.2147/IJWH.S158913
    1. Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. (2019) 20:821–35. 10.1080/14656566.2019.1574752
    1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. (2000) 96:351–8. 10.1097/00006250-200009000-00007
    1. Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric. (2018) 21:96–100. 10.1080/13697137.2018.1430131
    1. Nappi RE, Murina F, Perrone G, Villa P, Biglia N. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol. (2017) 69:370–80. 10.23736/S0026-4784.17.04064-3
    1. Avis NE, Crawford SL, Green R. Vasomotor symptoms across the menopause transition: differences among women. Obstet Gynecol Clin North Am. (2018) 45:629–40. 10.1016/j.ogc.2018.07.005
    1. Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause. (2018) 25:1331–8. 10.1097/GME.0000000000001237
    1. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas. (2009) 63:138–41. 10.1016/j.maturitas.2009.03.021
    1. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. (2014) 17:3–9. 10.3109/13697137.2013.871696
    1. Mitchell CM, Waetjen LE. Genitourinary changes with aging. Obstet Gynecol Clin North Am. (2018) 45:737–50. 10.1016/j.ogc.2018.07.010
    1. Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N, EVES Study Investigators . The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. (2018) 21:286–91. 10.1080/13697137.2018.1446930
    1. Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, et al. . Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. (2013) 5:437–47. 10.2147/IJWH.S44579
    1. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. (2013) 10:1790–9. 10.1111/jsm.12190
    1. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. (2016) 19:188–97. 10.3109/13697137.2015.1107039
    1. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)—results from an international survey. Climacteric. (2012) 15:36–44. 10.3109/13697137.2011.647840
    1. Nappi RE, Liekens G, Brandenburg U. Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey. Contraception. (2006) 73:493–500. 10.1016/j.contraception.2005.12.007
    1. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. (2010) 67:233–8. 10.1016/j.maturitas.2010.08.001
    1. Nappi RE, Palacios S, Particco M, Panay N. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: country-specific comparisons of postmenopausal women's perceptions, experiences and needs. Maturitas. (2016) 91:81–90. 10.1016/j.maturitas.2016.06.010
    1. Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The women's EMPOWER survey: women's knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. (2017) 14:425–33. 10.1016/j.jsxm.2017.01.011
    1. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. (2009) 6:2133–42. 10.1111/j.1743-6109.2009.01335.x
    1. Nappi RE, Cucinella L, Martella S, Rossi M, Tiranini L, Martini E. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas. (2016) 94:87–91. 10.1016/j.maturitas.2016.09.013
    1. Jannini EA, Nappi RE. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev. (2018) 6:384–95. 10.1016/j.sxmr.2017.11.002
    1. Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. (1995) 22(Suppl. 1):S1–5. 10.1016/0378-5122(95)00956-6
    1. Palma F, Xholli A, Cagnacci A, as the Writing Group of the AGATA Study . The most bothersome symptom of vaginal atrophy: evidence from the observational AGATA study. Maturitas. (2018) 108:18–23. 10.1016/j.maturitas.2017.11.007
    1. Palma F, Volpe A, Villa P, Cagnacci A, Writing Group of GATA Study . Vaginal Atrophy of Women in Postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. (2016) 83:40–4. 10.1016/j.maturitas.2015.09.001
    1. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. (2017) 14:413–24. 10.1016/j.jsxm.2017.01.010
    1. Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. (2019) 26:124–31. 10.1097/GME.0000000000001194
    1. Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, et al. . Female sexual health: barriers to optimal outcomes and a roadmap for improved patient-clinician communications. J Womens Health. (2019) 28:432–43. 10.1089/jwh.2018.7352
    1. Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, et al. . Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. (2010) 13:103–20. 10.3109/13697130903437615
    1. Parish SJ, Hahn SR, Goldstein SW, Giraldi A, Kingsberg SA, Larkin L, et al. . The International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women. Mayo Clin Proc. (2019) 94:842–56. 10.1016/j.mayocp.2019.01.009
    1. Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. (2014) 21:1063–8. 10.1097/GME.0000000000000329
    1. Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. . Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. (2016) 215:704–11. 10.1016/j.ajog.2016.07.045
    1. Lewis FM. Vulval symptoms after the menopause—Not all atrophy!. Post Reprod Health. (2015) 21:146–50. 10.1177/2053369115608019
    1. Vieira-Baptista P, Donders G, Margesson L, Edwards L, Haefner HK, Pérez-López FR. Diagnosis and management of vulvodynia in postmenopausal women. Maturitas. (2018) 108:84–94. 10.1016/j.maturitas.2017.11.003
    1. Johnston SL. Pelvic floor dysfunction in midlife women. Climacteric. (2019) 11:1–7. 10.1080/13697137.2019.1568402
    1. Shifren JL, Zincavage R, Cho EL, Magnavita A, Portman DJ, Krychman ML, et al. . Women's experience of vulvovaginal symptoms associated with menopause. Menopause. (2019) 26:341–9. 10.1097/GME.0000000000001275
    1. Sarrel PM. Sexuality and menopause. Obstet Gynecol. (1990) 75:26S−35S. 10.1097/00006250-199004001-00006
    1. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones JAMA. (1983) 249:2195–8. 10.1001/jama.1983.03330400041022
    1. Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, et al. . The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause. (2018) 25:837–47. 10.1097/GME.0000000000001138
    1. Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. (2019) 26:220–4. 10.1097/GME.0000000000001177
    1. Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. (2018) 6:558–71. 10.1016/j.sxmr.2018.03.005
    1. Cotreau MM, Chennathukuzhi VM, Harris HA, Han L, Dorner AJ, Apseloff G, et al. . A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas. (2007) 58:366–76. 10.1016/j.maturitas.2007.09.009
    1. Sturdee DW, Panay N, International Menopause Society Writing Group . Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. (2010) 13:509–22. 10.3109/13697137.2010.522875
    1. Forsberg JG. A morphologist's approach to the vagina – age-related changes and estrogen sensitivity. Maturitas. (1995) 22:S7–S15. 10.1016/0378-5122(95)00957-4
    1. Caillouette JC, Sharp CF, Jr, Zimmerman GJ, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol. (1997) 176:1270–5. 10.1016/S0002-9378(97)70345-4
    1. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. (2003) 62:45–51. 10.1016/S0090-4295(03)00676-9
    1. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. (2005) 52 (Suppl. 1):S46–52. 10.1016/j.maturitas.2005.06.014
    1. Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol. (2008) 51:549–55. 10.1097/GRF.0b013e3181809a26
    1. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. (2009) 12:279–85. 10.1080/13697130902814751
    1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvo-vaginal atrophy. Mayo Clin Proc. (2010) 85:87–94. 10.4065/mcp.2009.0413
    1. Stika CS. Atrophic vaginitis. Dermatol Ther. (2010) 23:514–22. 10.1111/j.1529-8019.2010.01354.x
    1. Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. (2016) 91:42–50. 10.1016/j.maturitas.2016.05.015
    1. Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. . Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. (2018) 25:1321–30. 10.1097/GME.0000000000001236
    1. Basaran M, Kosif R, Bayar U, Civelek B. Characteristics of external genitalia in pre- and postmenopausal women. Climacteric. (2008) 11:416–21. 10.1080/13697130802366670
    1. Mannella P, Palla G, Bellini M, Simoncini T. The female pelvic floor through midlife and aging. Maturitas. (2013) 76:230–4. 10.1016/j.maturitas.2013.08.008
    1. Calleja-Agius J, Brincat M.P. The urogenital system and the menopause. Climacteric. (2015) 18(Suppl. 1):18–22. 10.3109/13697137.2015.1078206
    1. Nappi RE. New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric. (2007) 10(Suppl. 2):105–8. 10.1080/13697130701599876
    1. Bachmann GA, Notelovitz M, Kelly SJ, Thompson C, Owens A. Long-term non-hormonal treatment of vaginal dryness. Clin Pract Sexuality. (1992) 8:3–8.
    1. Panay N. Genitourinary syndrome of the menopause–dawn of a new era? Climacteric. (2015) 18(Suppl. 1):13–7. 10.3109/13697137.2015.1070564
    1. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health. (2010) 19:425–32. 10.1089/jwh.2009.1384
    1. Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the post menopause—cytology, histology and pH as methods of assessment. Maturitas. (1995) 21:51–6. 10.1016/0378-5122(94)00863-3
    1. Tucker KM, Godha K, Mirkin S, Archer DF. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. Menopause. (2008) 25:762–6. 10.1097/GME.0000000000001081
    1. Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. (2015) 26:15–28. 10.1007/s00192-014-2464-0
    1. Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N, EVES Study Investigators . The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. Menopause. (2019) 26:485–91. 10.1097/GME.0000000000001260
    1. Simon JA, Archer DF, Kagan R, Bernick B, Graham S, Constantine GD, et al. . Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial. Menopause. (2017) 24:1003–10. 10.1097/GME.0000000000000880
    1. Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. . Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. (2018) 25:596–608. 10.1097/GME.0000000000001121
    1. Sadovsky R, Basson R, Krychman M, Morales AM, Schover L, Wang R, et al. . Cancer and sexual problems. J Sex Med. (2010) 7:349–73. 10.1111/j.1743-6109.2009.01620.x
    1. Nappi RE, Cucinella L, Martini E, Rossi M, Tiranini L, Martella S, et al. . Sexuality in premature ovarian insufficiency. Climacteric. (2019) 22:289–95. 10.1080/13697137.2019.1575356
    1. Doumouchtsis SK, Chrysanthopoulou EL. Urogenital consequences in ageing women. Best Pract Res Clin Obstet Gynaecol. (2013) 27:699–714. 10.1016/j.bpobgyn.2013.03.007
    1. Bolton PJ, Selo-Ojeme DO. Endometrial adenocarcinoma: an unusual presentation with acute urinary retention secondary to haematocolpos. J Obstet Gynaecol. (1999) 19:553–4. 10.1080/01443619964508
    1. Segal S, Harvie HS, Siegelman E, Arya LA. Severe atrophic vaginitis causing vaginal synechiae and hematocolpos at menopause. Menopause. (2011) 18:333–5. 10.1097/gme.0b013e3181f3285a
    1. Stiles M, Redmer J, Paddock E, Schrager S. Gynecologic issues in geriatric women. J WomensHealth. (2012) 21:4–9. 10.1089/jwh.2011.2803
    1. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. (2007) 357:762–74. 10.1056/NEJMoa067423
    1. Thomas HN, Hess R, Thurston RC. Correlates of sexual activity and satisfaction in midlife and older women. Ann Fam Med. (2015) 13:336–42. 10.1370/afm.1820
    1. Nappi RE, Albani F, Santamaria V, Tonani S, Magri F, Martini E, et al. . Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas. (2010) 67:78–83. 10.1016/j.maturitas.2010.05.008
    1. Nappi RE, Verde JB, Polatti F, Genazzani AR, Zara C. Self-reported sexual symptoms in women attending menopause clinics. Gynecol Obstet Invest. (2002) 53:181–7. 10.1159/000058371
    1. Pinkerton JV, Bushmakin AG, Komm BS, Abraham L. Relationship between change in vulvar-vaginal atrophy and changes in sexual functioning. Maturitas. (2017) 100:57–63. 10.1016/j.maturitas.2017.03.315
    1. Gass ML, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, et al. . Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause. (2011) 18:1160–71. 10.1097/gme.0b013e3182227ebd
    1. Weber AM, Walters MD, Schover LR, Mitchinson A. Vaginal anatomy and sexual function. Obstet Gynecol. (1995) 86:946–9. 10.1016/0029-7844(95)00291-X
    1. Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. (2013) 10:2232–41. 10.1111/jsm.12235
    1. Simon JA, Davis SR, Althof SE, Chedraui P, Clayton AH, Kingsberg SA, et al. . Sexual well-being after menopause: an International Menopause Society White Paper. Climacteric. (2018) 21:415–27. 10.1080/13697137.2018.1482647
    1. Nappi RE, Mattsson LÅ, Lachowsky M, Maamari R, Giraldi A. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women andtheir partners in Northern and Southern Europe. Maturitas. (2013) 75:373–9. 10.1016/j.maturitas.2013.05.003
    1. Domoney C, Currie H, Panay N, Maamari R, Nappi RE. The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause Int. (2013) 19:69–76. 10.1177/1754045313484139
    1. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the vaginal health: insights, views & attitudes survey. Menopause. (2013) 20:1043–8. 10.1097/GME.0b013e318287342d
    1. Nappi RE, Krychman ML. The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey. Climacteric. (2016) 19:252–5. 10.3109/13697137.2016.1173026
    1. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas. (2004) 49:292–303. 10.1016/j.maturitas.2004.06.019
    1. Gass M, Larson J, Cochrane B, Manson JE, Lane D, Barnabei V, et al. . Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials. Menopause. (2018) 25:252–64. 10.1097/GME.0000000000000994
    1. Castelo-Branco C, Biglia N, Nappi RE, Schwenkhagen A, Palacios S. Characteristics of post-menopausal women with genitourinary syndrome of menopause: implications for vulvovaginal atrophy diagnosis and treatment selection. Maturitas. (2015) 81:462–9. 10.1016/j.maturitas.2015.05.007
    1. Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause. (2014) 21:137–42. 10.1097/GME.0b013e318295236f
    1. DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health. (2015) 24:713–22. 10.1089/jwh.2014.5177
    1. Lang K, Alexander IM, Simon J, Sussman M, Lin I, Menzin J, et al. . The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative survey. J Womens Health. (2015) 24:374–83. 10.1089/jwh.2014.4907
    1. EuroQoL Group EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. (1990) 16:199–208. 10.1016/0168-8510(90)90421-9
    1. Huang AJ, Gregorich SE, Kuppermann M, Nakagawa S, Van Den Eeden SK, Brown JS, et al. . Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. (2015) 22:144–54. 10.1097/GME.0000000000000281
    1. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. . The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. (2000) 26:26191–208. 10.1037/t28568-000
    1. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. (2008) 5:357–64. 10.1111/j.1743-6109.2007.00672.x
    1. Hunter MM, Nakagawa S, Van Den Eeden SK, Kuppermann M, Huang AJ. Predictors of impact of vaginal symptoms in postmenopausal women. Menopause. (2016) 23:40–6. 10.1097/GME.0000000000000482
    1. Nappi RE, Seracchioli R, Salvatore S, Cagnacci A, Di Paolantonio T, Busacca M, et al. . Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. (2019) 35:453–9. 10.1080/09513590.2018.1563883
    1. Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE, EVES Study Investigators . Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. (2019) 124:55–61. 10.1016/j.maturitas.2019.03.013
    1. Nappi RE, Biglia N, Cagnacci A, Di Carlo C, Luisi S, Paoletti AM. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol. (2016) 32:602–6. 10.1080/09513590.2016.1183627
    1. Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med. (2013) 10:1567–74. 10.1111/jsm.12120
    1. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. (2016) 31:CD001500 10.1002/14651858.CD001500.pub3
    1. Rees M, Pérez-López FR, Ceasu I, Depypere H, Erel T, Lambrinoudaki I, et al. . EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas. (2012) 73:171–4. 10.1016/j.maturitas.2012.06.009
    1. NAMS (2013). Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 20, 888–902; quiz 903-4. 10.1097/GME.0b013e3182a122c2
    1. Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. (2016) 19:60–5. 10.3109/13697137.2015.1113517
    1. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. (2016) 19:151–61. 10.3109/13697137.2015.1124259
    1. Mercier J, Morin M, Zaki D, Reichetzer B, Lemieux MC, Khalifé S, et al. . Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. Maturitas. (2019) 125:57–62. 10.1016/j.maturitas.2019.03.002
    1. Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. . Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. (2017) 49:137–59. 10.1002/lsm.22637
    1. Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ. (2010) 340:c810. 10.1136/bmj.c810
    1. Corona G, Rastrelli G, Maseroli E, Forti G, Maggi M. Sexual function of the ageing male. Best Pract Res Clin Endocrinol Metab. (2013) 27:581–601. 10.1016/j.beem.2013.05.007
    1. Miner M, Esposito K, Guay A, Montorsi P, Goldstein I. Cardiometabolic risk and female sexual health: the Princeton III summary. J Sex Med. (2012) 9:641–51; quiz 652. 10.1111/j.1743-6109.2012.02649.x
    1. Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet. (2007) 369:409–24. 10.1016/S0140-6736(07)60197-4
    1. Constantine GD, Bruyniks N, Princic N, Huse D, Palmer L, Lenhart G, et al. . Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy. Curr Med Res Opin. (2014) 30:143–8. 10.1185/03007995.2013.850068
    1. Phillips NA, Bachmann GA. Genitourinary syndrome of menopause: common problem, effective treatments. Cleve Clin J Med. (2018) 85:390–8. 10.3949/ccjm.85a.15081

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi